FAIR VALUE - Narrative (Details)						3 Months Ended	6 Months Ended		12 Months Ended
	Mar. 17, 2025 USD ($)	Sep. 16, 2024 USD ($)	Feb. 22, 2024 USD ($)	Dec. 12, 2023 USD ($)	May 17, 2021 USD ($)	Dec. 31, 2024 USD ($)	Jun. 30, 2025 USD ($) shares	Jun. 30, 2024 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($) guarantee
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money Market Fund						$ 84,277,000	$ 136,280,000			$ 84,277,000
Interest rate swap						4,897,000	$ 2,812,000			4,897,000
Achievement of milestones payment period							24 months
Payments on contingent consideration							$ 0	$ 12,500,000
Contingent consideration, Novitium						10,900,000	12,600,000			10,900,000
Payments for royalties	$ 17,300,000
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Additional contingent consideration							46,500,000
Payments on contingent consideration			$ 12,500,000	$ 12,500,000
Contingent consideration, Novitium						10,854,000	12,572,000			10,854,000
Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium						9,000,000	6,000,000			$ 9,000,000
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of payments							$ 21,500,000
Net profit generated by the sales							20.00%
Collaborative arrangement, percentage of net profit generated by sales, quarterly payment due, accrued							$ 45,000
CG Oncology
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Shares held (in shares) | shares							219,925
Closing price							$ 26.00
Accrued Licensor Payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of payments							5,700,000
Up-front payment					$ 75,000,000
Number of quarterly guaranteed payment | guarantee										4
Additional milestone payment										$ 7,500,000
Accrued Licensor Payments | Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Collaborative arrangement royalty payable on net revenue revenue threshold									$ 70,000,000
Eye Point Agreements Member
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of payments							11,400,000
Payments for royalties						$ 1,900,000
Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration classified as equity, fair value disclosure							$ 6,000,000
2026 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, milestone payment, revenue achievement		$ 140,000,000.0
Business combination, milestone payment multiplier		0.25
Business combination, divisible revenue		$ 10,000,000
2027 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, milestone payment, revenue achievement		$ 160,000,000.0
Business combination, milestone payment multiplier		0.25
Business combination, divisible revenue		$ 15,000,000
Contingent consideration, milestone payment, CVRs agreement business days		15 days